mefloquine plus artesunate
Phase 3Small molecule
Medicines for Malaria Venturemefloquine plus artesunate is one of 99 small molecule programs targeting Plasmodium falciparum malaria. It is currently in Phase 3.
3
Indications
3
Total Trials
0
Active Trials
98
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
479 competitors in Malaria
#DrugCompanyPhaseTrials
1Pyronaridine-Artesunate
Medicines for Malaria VenturePhase 3
mefloquine plus artesunate
Medicines for Malaria VenturePhase 3
Biltricide
BayerPreclinical
Stelara
Johnson & JohnsonPreclinical
Hydroxychloroquine Sulfate
NovartisPreclinical
Iron
WWatson Pharmaceuticals
Preclinical
IV LBH589
NovartisPreclinical
IV Ceftriaxone
RRESnTEC, Institute of Research
Preclinical
RTS,S/AS01E
GSKPreclinical
Malarone
Medicines for Malaria VenturePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sickle Cell Disease1 trial
Malaria1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mefloquine plus artesunate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details